Navigation Links
Targeted toxin active in platinum-resistant ovarian cancers
Date:4/6/2013

WASHINGTON -- A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research. The findings (abstract LB-290) will be discussed at a press conference on Saturday, April 06, 2013, 1:00 p.m., ET, in Room 153, in the Washington Convention Center and later at an oral presentation on Tuesday, April 09, 2013, 4:00 p.m. to 4:20 p.m. in room 146, in the Washington Convention Center.

Joyce Liu, MD, MPH, first author of the study, said that among 29 patients who received the antibody-drug conjugate at what was found to be the maximum tolerated dose, there was one complete response and four partial responses. "In addition, there were additional patients with prolonged stable disease who were able to stay on treatment," said Liu, of the gynecologic oncology treatment center at Dana-Farber.

The responses all occurred in patients whose tumors had high expression of the MUC16 protein to which the drug is targeted. Known as DMUC5754A, the drug conjugate consists of an antibody, which recognizes the MUC16 protein expressed by ovarian cancer cells, fused to a toxin, MMAE, which prevents cancer cells from dividing. Targeting the drug conjugate specifically to ovarian cancer cells reduced adverse effects of the toxin on healthy tissues and organs, said Liu. She called the safety profile "encouraging." Most common adverse effects were fatigue, nausea, and vomiting. This phase 1 multicenter trial is the first use in humans of DMUC5754A, and the responses, which Liu called "a nice sign of activity in a very challenging type of ovarian cancer to treat," merit further testing in a phase II trial, which is being planned. "If the activity of this drug is confirmed in additional trials, this will represent a novel type of therapy for ovarian cancer," Liu said.


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The future of personalized and targeted cancer therapy
2. Medicaid Fraud in New York Targeted by New House Report
3. Targeted Equine Nutrition Launches New Website For Horse Lovers
4. Banning food ads targeted at kids
5. Study finds tiny, targeted drug particles may be effective in treating chronic diseases
6. Blood Test Plus Targeted Care May Stop Heart Failure Before It Starts
7. Medical Advertising Agency bryantBROWN Healthcare Introduces Targeted Point-of-Care Promotions to Help Law Firms Connect More Directly With Patients and Caregivers
8. Tuberculosis and neglected diseases targeted by new center
9. Lancet Oncology: Long-term side-effects of targeted therapies in pediatric cancer patients
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Quick Weight Loss for Women of All Ages With Targeted Diet Plan
11. High Complexity Laboratory Testing Supports New Targeted Therapies for Leukemias and Lymphomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... / Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s ... to Work in Healthcare by Modern Healthcare and will be honored at an ... its eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF International announced that West ... day treatment and intensive family based services. , By pursuing and achieving accreditation, ... pursuit of excellence. As a nonprofit charity for more than 50 years, West ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Northridge ... on Zoom teeth whitening. For just $199, patients can currently receive a one hour ... in-office teeth whitening procedures, but it includes a number of unique features that can ...
Breaking Medicine News(10 mins):Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... Boston, MA -- Eating disorders among adolescent girls and ... and lead to dangerous weight-control behaviors, such as self-induced ... weight. The middle school age is a high risk ... dangerous weight-control behaviors that affect millions of Americans. Researchers ...
... 8.7 percent of U.S. children age 8 to ... fewer than half receive treatment, according to a ... Pediatrics & Adolescent Medicine, one of the JAMA/Archives ... of attention-deficit/hyperactivity disorder (ADHD) is on the rise, ...
... age 12 to 19 years who received family-based treatment ... than those who received supportive psychotherapy, which explores the ... in the September issue of Archives of General Psychiatry, ... is a disabling eating disorder with a prevalence of ...
... need, researchers say , , MONDAY, Sept. 3 (HealthDay News) ... disorder (ADHD), but only 32 percent of them are ... conclusion of a landmark new study, the first of ... standard" of diagnostic criteria -- the Diagnostic and Statistical ...
... SDAX as Per September 6, 2007 ... Outside the Normal Schedule, Decision on Possible ... Germany, September 3 Gerresheimer AG has,been listed in the Prime Standard ... largest IPOs of the year, with a total,issue volume of more than ...
... Belgium, September 3 KFH has announced that ... ISO 13485 and ISO,9001:2000 quality management systems with ... Dr Sally Sennitt, MD, says: "We are delighted,to ... systems,through working with BSI. It is a major ...
Cached Medicine News:Health News:School-based overweight prevention program may cut risk of eating disorders among girls 2Health News:Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 2Health News:Family-based treatment more effective than supportive psychotherapy in treating bulimia 2Health News:9% of U.S. Kids Have ADHD 2Health News:9% of U.S. Kids Have ADHD 3
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
(Date:8/28/2015)... , Joint research by Prof. Kim ... , Published in ,Stem Cells Translational Medicine, (IF ... multiple IV administration of Adipose-derived MSC , Increase ... , Commercialization within 5 years expected ... adult mesenchymal stem cells (MSCs) may extend healthy life ...
(Date:8/28/2015)... , August 28, 2015 The ... reach USD 49.12 billion by 2020, growing at a ... a new report by Grand View Research, Inc. Monitoring ... of 49.7% from 2014 to 2020.      ... population along with rising incidences of chronic diseases such ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... , SANTA ROSA, Calif. , Feb. 16 ... Osseoplasty™ procedures in Europe . The procedures were performed in ... Incorporado, SL, the largest independent medical device distributor in Europe ... weeks in the United Kingdom , Germany and ...
... , , CRANBURY, N.J. , ... today announced financial results for the fourth quarter and full year ... product pipeline related to its key strategic priorities for 2010.  Additionally, ... achieve its key milestone of completing enrollment for its Phase 3 ...
Cached Medicine Technology:Osseon Launches in Europe 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 11
...
...
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium....
Solid 13.5 mm wide by 5 mm deep blades. Edge of blades serrated. Dull finish....
Medicine Products: